Accumulation of Wild Type p53 Protein in Human Astrocytomas

Cancer Research

Volumn 53, Issue 15, 1993, Pages 3465-3467

  Rubio, Mari Paz ^a   Von Deimling, Andreas ^b   Yandell, David W ^c   Wiestler, Otmar D ^b   Gusella, James F ^d   Louis, David N ^a  

^a Neurosurgical and Neurology Services   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Neurology Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; ASTROCYTOMA CELL; DNA DAMAGE; EXON; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONSENSE MUTATION; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL;

ASTROCYTOMA; BASE SEQUENCE; GENE AMPLIFICATION; GENES, P53; HUMAN; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; PROTEIN P53; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027213985     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Chung, R.Y., Whaley, J., Kley, N., Anderson, K., Louis, D.N., Menon, A., Hettlich, C., Freiman, R., Hedley-Whyte, E.T., Martuza, R., Jenkins, R., Yandell, D., and Seizinger, B.R. TP53 mutation and 17p deletion in human astrocytomas. Genes Chromos. Cancer, 3: 323-331, 1991.
2. Louis, D.N., von Deimling, A., Chung, R.Y., Rubio, M.P., Whaley, J.H., Ohgaki, H., Eibl, R., Wiestler, O. D., Thor, A.D., and Seizinger, B.R. Comparative study of p. 3 gene and protein alterations in human astrocytoma. J. Neuropathol. Exp. Neurol., 52: 31-38, 1993.
3. Bennett, W.P., Hollstein, M.C., He, A., Zhu, S.M., Resau, J.H., Trump, B.F., Metcalf, R.A., Welsh, J.A., Midgley, C., Lane, D.P., and Harris, C.C. Archival analysis of p. 3 genetic and protein alterations in Chinese esophageal cancer. Oncogene, 6: 1779-1784, 1991.
4. Unman, T.A., Bennett, W.P., Metcalf, R.A., Reddel, R., Welsh, J.A., Ecker, J., Modali, R.V., Ullrich, S., Ramano, J.W., Appella, E., Testa, J.R., Gerwin, B.I., and Harris, C.C. p. 3 mutations, ras mutations, and p. 3-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res., 57: 4090-4096, 1991.
5. Rodrigues, N.R., Rowan, A., Smith, M.E.F., Kerr, I.B., Bodmer, W.F., Gannon, J.V., and Lane, D.P. p. 3 mutations in colon cancer. Proc. Natl. Acad. Sci. USA, 87: 7555-7559, 1990.
6. Momand, J., Zambetti, G.P., Olson, D.C., George, D., and Levine, A.J. The mdm-2 oncogene product forms a complex with the p. 3 protein and inhibits p. 3-mediated transactivation. Cell, 69: 1237-1245, 1992.
7. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L., and Vogelstein, B. Amplification of a gene encoding a p. 3-associated protein in human sarcomas. Nature (Lond.), 358: 80-83, 1992.
8. von Deimling, A., Eibl, R.H., Ohgaki, H., Louis, D.N., von Ammon, K., Petersen, I., Kleihues, P., Chung, R.Y., Wiestler, O.D., and Seizinger, B.R. p. 3 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res., 52: 2987-2990, 1992.
9. Toguchida, J., Yamaguchi, T., Ritchie, B., Beauchamp, R.L., Dayton, S.H., Herrera, G.E., Yamamuro, T., Kotoura, Y., Sasaki, M.S., Little, J.B., Weichselbaum, R.R., Ishizaki, K., and Yandell, D.W. Mutation spectrum of the p. 3 gene in bone and soft tissue sarcomas. Cancer Res., 52: 6194-6199, 1992.
10. Banks, L., Matlashewski, G., and Crawford, L. Isolation of human-p. 3-specific monoclonal antibodies and their use in the studies of p. 3 expression. Eur. J. Bio-chem., 739: 529-534, 1986.
11. Gannon, J.V., Greaves, R., Iggo, R., and Lane, D.P. Activating mutations in p. 3 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9: 1595-1602, 1990.
12. Frankel, R.H., Bayona, W., Koslow, M., and Newcomb, E.W. p. 3 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res., 52: 1427-1433, 1992.
13. Fults, D., Brockmeyer, D., Tullous, M.W., Pedone, C.A., and Cawthon, R.M. p. 3 mutation and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res., 52: 674-679, 1992.
14. Mashiyama, S., Murakami, Y., Yoshimoto, T., Sekiya, T., and Hayashi, K. Detection of p. 3 mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene, 6: 1313-1318, 1991.
15. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. p. 3 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
16. Louis, D.N., Rubio, M.P., Correa, K., Gusella, J.F., and von Deimling, A. Molecular genetics of pediatric brain stem gliomas. J. Neuropathol. Exp. Neurol., in press, 1993.
17. Takahashi, T., D'Amico, D., Chiba, I., Buchhagen, D.L., and Minna, J.D. Identification of intronic point mutations as an alternative mechanism for p. 3 inactivation in lung cancer. J. Clin. Invest., 86: 363-369, 1990.
18. Thompson, A.M., Anderson, T.J., Condie, A., Prosser, J., Chetty, U., Carter, D.C., Evans, H.J., and Steel, C.M. p. 3 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int. J. Cancer, 50: 528-32, 1992.
19. Borresen, A.L., Hovig, E., Smith-Soresen, B., Malkin, D., Lystad, S., Andersen, T.I., Nesland, J.M., Isselbacher, K.J., and Friend, S.I. Constant denaturant gel electrophoresis as a rapid screening technique for p. 3 mutations. Proc. Natl. Acad. Sci. USA, 88: 8405-8409, 1991.
20. Kupryjanczyk, J., Thor, A.D., Beauchamp, R., Merritt, V., Edgerton, S.M., Bell, D.A., and Yandell, D.W. p. 3 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA, 90: 4961-4965, 1993.
21. Davidoff, A.M., Pence, J.C., Shorter, N.A., Iglehart, J.D., and Marks, J.R. Expression of p. 3 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene, 7: 127-133, 1992.
22. Barnes, D.M., Hanby, A.M., Gillett, C.E., Mohammed, S., Hodgson, S., Borrow, L.G., Leigh, I.M., Purkis, T., MacGeoch, C., Spurr, N.K., Bartek, J., Vojtesek, B., Picksley, S.M., and Lane, D.P. Abnormal expression of wild type p. 3 protein in normal cells of a cancer family patient. Lancet, 340: 259-263, 1992.
23. Moll, U.M., Riou, G., and Levine, A.J. Two distinct mechanisms alter p. 3 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262-6, 1992.
24. Tuck, S.P., and Crawford, L. Overexpression of normal human p. 3 in established fibroblasts leads to their tumorigenic conversion. Oncogene Res., 4: 81-96, 1989.
25. Mercer, W.E., and Baserga, R. Expression of the p. 3 protein during the cell cycle of human peripheral blood lymphocytes. Exp. Cell Res., 160: 31-36, 1985.
26. Fritsche, M., Haessler, C., and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p. 3 by DNA-damaging agents. Oncogene, 8: 307-318, 1993.
27. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A.L. Increased expression of mutant forms of p. 3 oncogene in primary lung cancer. Lancet, 335: 675-679, 1990.
28. Finlay, C.A., Hinds, P.W., Tan, T.H., Eliyahu, D., Oren, M., and Levine, A.J. Activating mutations for transformation by p. 3 produce a gene product that forms an hsc70-p. 3 complex with an altered half-life. Mol. Cell. Biol., 8: 531-539, 1988.
29. Saxena, A., Clark, W.C., Robertson, J.T., Ikejiri, B., Oldfield, E.H., and Ali, I.U. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p. 3 in malignant astrocytoma. Cancer Res., 52: 6716-6721, 1992.
30. Vogelstein, B., and Kinzler, K.W. p. 3 function and dysfunction. Cell, 70: 523-526, 1992.
31. Jaros, E., Perry, R.H., Adam, L., Kelly, P.J., Crawford, P.J., Kalbag, R.M., Mendelow, A.D., Sengupta, R.P., and Pearson, A.D.J. Prognostic implications of p. 3 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br. J. Cancer, 66: 373-385, 1992.